公开(公告)号：US11162079B2

公开(公告)日：2021-11-02

申请号：US16870959

申请日：2020-05-09

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Sonja Schrepfer ,  Tobias Deuse

IPC: A61K9/127 ,  C12N5/074 ,  C12N5/0735 ,  C12N5/077

Abstract: The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO−) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO− cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh− (“O−”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O− parent cell line. These new, novel HIPO− cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O− pluripotent stem cells (iPSCO−) and O− embryonic stem cells (ESCO−). The invention further provides universally acceptable “off”-the-shelf pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

公开(公告)号：US20230348862A1

公开(公告)日：2023-11-02

申请号：US18127936

申请日：2023-03-29

Applicant: The Regents of the University of California

Inventor： Sonja Schrepfer ,  Tobias Deuse

IPC: C12N15/113 ,  C12N15/52 ,  C12N15/85 ,  C12N5/074

CPC classification number: C12N5/0696 ,  C12N15/1138 ,  C12N15/52 ,  C12N15/85 ,  C12N2310/20 ,  C12N2501/599 ,  C12N2840/005 ,  C12N2840/007 ,  C12Y207/01021 ,  C12Y305/04001

Abstract: The invention provides pluripotent cells that are used therapeutically for regenerating tissues but avoid rejection by subjects that receive them. In particular, the invention provides hypo-immunogenic pluripotent cells that avoid host immune rejection. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

公开(公告)号：US20220213434A1

公开(公告)日：2022-07-07

申请号：US17607841

申请日：2020-05-09

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Sonja Schrepfer ,  Tobias Deuse

IPC: C12N5/0735 ,  C12N15/113 ,  C12N5/074

Abstract: The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, and hypo-immune pluripotent cells that are ABO blood type O Rhesus Factor negative and evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

公开(公告)号：US20210308183A1

公开(公告)日：2021-10-07

申请号：US17260222

申请日：2019-07-17

Applicant: The Regents of the University of California

Inventor： Sonja Schrepfer ,  Tobias Deuse

IPC: A61K35/17 ,  C12N15/11 ,  C12N9/22 ,  C12N5/0783

Abstract: The invention provides universally acceptable “off-the-shelf” hypoimmune pluripotent (HIP) cells and hypoimmune chimeric antigen receptor T (CAR-T) cells derived from the HIP cells. The engineered therapeutic cells can be administered to subjects as an adoptive cell-based immunotherapy to treat cancer.

公开(公告)号：US12221622B2

公开(公告)日：2025-02-11

申请号：US16870960

申请日：2020-05-09

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Sonja Schrepfer ,  Tobias Deuse

IPC: C12N5/0735 ,  A61K35/34 ,  A61K35/545 ,  C12N5/074 ,  C12N9/22 ,  C12N15/113

Abstract: The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, hypo-immune pluripotent cells, cells that have been derived therefrom, and cells that have been biologically differentiated therefrom into particular tissue lineages that are ABO blood type O Rhesus Factor negative or otherwise evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

公开(公告)号：US20210292715A1

公开(公告)日：2021-09-23

申请号：US17260224

申请日：2019-07-17

Applicant: The Regents of the University of California

Inventor： Sonja Schrepfer ,  Tobias Deuse

IPC: C12N5/074 ,  C12N5/077

Abstract: The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.